Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Cristina Astrid Tentori, Caterina Gregorio, Marie Robin, Nico Gagelmann, Carmelo Gurnari, Somedeb Ball, Juan Carlos Caballero Berrocal, Luca Lanino, Saverio D'Amico, Marta Spreafico, Giulia Maggioni, Erica Travaglino, Elisabetta Sauta, Manja Meggendorfer, Lin-Pierre Zhao, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Maria Borin, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Jan Philipp Bewersdorf, Olivier Nibourel, Marina Díaz-Beyá, Andres Jerez, Francisca Maria Hernandez, Kyra Velázquez Kennedy, Blanca Xicoy, Marta Ubezio, Alessia Campagna, Antonio Russo, Gabriele Todisco, Daniele Mannina, Stefania Bramanti, Matteo Zampini, Elena Riva, Marilena Bicchieri, Gianluca Asti, Filippo Viviani, Alessandro Buizza, Benedetta Tinterri, Andrea Bacigalupo, Alessandro Rambaldi, Francesco Passamonti, Fabio Ciceri, Victor Savevski, Armando Santoro, Najla H Al Ali, David A Sallman, Francesc Sole, Guillermo Garcia-Manero, Ulrich Germing, Shahram Kordasti, Valeria Santini, Guillermo Sanz, Wolfgang Kern, Anne Sophie Kubasch, Uwe Platzbecker, Maria Diez-Campelo, Jaroslaw P. Maciejewski, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Amer M. Zeidan, Gastone Castellani, Rami S. Komrokji, Francesca Ieva, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 197.

https://doi.org/10.1182/blood-2023-182194

Published: 2023

Journal Articles

Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients

Luca Lanino, Anthony M. Hunter, Claudia Sala, Daniele Dall'Olio, Lorenzo Dall'Olio, Lisa Pleyer, Blanca Xicoy, Manja Meggendorfer, Elisabetta Sauta, Erica Travaglino, Marie Robin, Laura Palomo, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Giulia Rivoli, Massimo Bernardi, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Filippo Viviani, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Armando Santoro, Wolfgang Kern, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Angela Consagra, Najla H Al Ali, David A Sallman, Pierre Fenaux, Raphael Itzykson, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2023-184536

Published: 2023

Journal Articles

Clinical Characterization of Fusion Genes in Acute Myeloid Leukemia without Recurrent Genetic Abnormalities

Francesca Guijarro, Marc Dabad, Mònica López-Guerra, Alex Bataller Torralba, Sandra Castaño-Díez, Carlos Jimenez-Vicente, Marta Garrote, José Ramón Álamo Moreno, Marta Pratcorona, Neus Villamor, Dolors Colomer, Silvia Bea, Dolors Costa, Anna Esteve-Codina, Marina Díaz-Beyá, Jordi Esteve

Blood (2023) 142 (Supplement 1): 6008.

https://doi.org/10.1182/blood-2023-188261

Published: 2023

Journal Articles

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Blood (2023) 142 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2023-186777

Published: 2023

Journal Articles

Chronic Myelomonocytic Leukemia (CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA ) Identify a High-Risk CMML Group Independent of Molecular-Cpss

Blood (2023) 142 (Supplement 1): 3231.

https://doi.org/10.1182/blood-2023-173311

Published: 2023

Journal Articles

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4230.

https://doi.org/10.1182/blood-2023-185484

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Blood (2023) 142 (Supplement 1): 3550.

https://doi.org/10.1182/blood-2023-179852

Published: 2023

Journal Articles

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 7018.

https://doi.org/10.1182/blood-2023-181076

Published: 2023

Journal Articles

Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 1132–1134.

https://doi.org/10.1182/blood-2022-159429

Published: 2022

Journal Articles

Design and in Vitro Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia

Alex Bataller Torralba, Néstor Tirado, Diego Sánchez-Martínez, Talía Velasco-Hernández, Aina Oliver-Caldés, Sandra Castaño-Díez, Francesca Guijarro, Marina Diaz-Beyá, Manel Juan, Pablo Engel, Clara Bueno, Pablo Menendez, Álvaro Urbano-Ispizua, Jordi Esteve

Blood (2021) 138 (Supplement 1): 4799.

https://doi.org/10.1182/blood-2021-153356

Published: 2021

Journal Articles

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Blood (2021) 138 (Supplement 1): 3486.

https://doi.org/10.1182/blood-2021-148263

Published: 2021

Journal Articles

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

María Diez-Campelo, Luis E. Benlloch, Emma Sasse, David Wormser, Leyla Hernandez Donoso, Silvia Colicino, Teresa Bernal, Antonieta Molero Yordi, Mar Tormo, Montserrat Arnan Sangerman, Guillermo Sanz, Marina Díaz-Beyá, María Teresa Cedena Romero, Andres Jerez, Brayan Merchán, David Valcárcel

Blood (2021) 138 (Supplement 1): 2605.

https://doi.org/10.1182/blood-2021-146019

Published: 2021

Journal Articles

Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-140680

Published: 2020

Journal Articles

A Revised International Prognostic Scoring System of 3.5 Points Stratifies Patients with Myelodysplastic Syndromes into 2 Risk Categories

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-136197

Published: 2020

Journal Articles

Myeloproliferative/Myelodysplastic Neoplasms Presenting All Diagnostic Criteria of Chronic Myelomonocytic Leukemia but with Absolute Peripheral Blood Monocytosis 0.5-1× 10 9 /L Should be Classified As CMML

Sandra Castaño-Díez, Monica Lopez-Guerra, PhD, Daniel Esteban, Francesca Guijarro, MD, Alex Bataller Torralba, MD, Paola Charry, MD, Carlos Castillo, MD, Carlos Jiménez-Vicente, MD, Colomer Dolors, María Rozman, MD, Jordi Esteve, Marina Diaz-Beyá, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-142819

Published: 2020

Journal Articles

Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project)

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-139160

Published: 2020

Journal Articles

Emergence of NPM1 Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia with NPM1 Mutation: Proposed Mechanisms of Clonal Evolution

Sandra Castaño-Díez, Monica Lopez-Guerra, PhD, Francesca Guijarro, MD, Alex Bataller Torralba, MD, Daniel Esteban, Carlos Castillo, MD, Carlos Jiménez-Vicente, MD, Paola Charry, MD, Colomer Dolors, María Rozman, MD, Jordi Esteve, Marina Diaz-Beyá, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-142740

Published: 2020

Journal Articles

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140670

Published: 2020

Journal Articles

Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease

Blood (2019) 134 (Supplement_1): 289.

https://doi.org/10.1182/blood-2019-128682

Published: 2019

Journal Articles

Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry

Blood (2019) 134 (Supplement_1): 1321.

https://doi.org/10.1182/blood-2019-128568

Published: 2019

NARROW

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients

Clinical Characterization of Fusion Genes in Acute Myeloid Leukemia without Recurrent Genetic Abnormalities

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Chronic Myelomonocytic Leukemia (CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA ) Identify a High-Risk CMML Group Independent of Molecular-Cpss

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes

Design and in Vitro Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival

A Revised International Prognostic Scoring System of 3.5 Points Stratifies Patients with Myelodysplastic Syndromes into 2 Risk Categories

Myeloproliferative/Myelodysplastic Neoplasms Presenting All Diagnostic Criteria of Chronic Myelomonocytic Leukemia but with Absolute Peripheral Blood Monocytosis 0.5-1× 10 9 /L Should be Classified As CMML

Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project)

Emergence of NPM1 Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia with NPM1 Mutation: Proposed Mechanisms of Clonal Evolution

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease

Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only